Loading clinical trials...
Loading clinical trials...
EGFR gene mutations are some of the most commonly occurring mutations in non-small cell lung cancer. Investigators have developed a DNA instability model that estimates a risk score to assess the likelihood of an individual acquiring a cancer-linked mutation. The aim of this study is to collect blood from both those diagnosed with EGFR positive lung cancer and healthy individuals, evaluate their gene sequence surrounding the EGFR landscape and use the cancer positive and healthy sequences to validate the risk assessment model, which may one day be used to provide insight on susceptibility of getting EGFR positive lung cancer or potentially other cancer types.
Age
18 - 100 years
Sex
FEMALE
Healthy Volunteers
Yes
Our Lady of the Lake Regional Medical Center
Baton Rouge, Louisiana, United States
Start Date
January 1, 2025
Primary Completion Date
December 31, 2025
Completion Date
December 31, 2025
Last Updated
March 20, 2025
20
ESTIMATED participants
blood draw
OTHER
Gene sequencing
OTHER
Lead Sponsor
Our Lady of the Lake Hospital
NCT06786468
NCT06621147
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT01532089